Physician profile
Alexia Clark
NPI 1265107213
$2,492.72
in general payments reported to CMS, 2019-2025
12 companies · $787 in 2025
The $787 reported for 2025 was more than what 88% of Pediatrics (Optometrist) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $509 · 2023: $562 · 2024: $634 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $606.49 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $510.42 | 2022-2025 | Total30, Rocklatan, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $224.14 | 2022-2025 | Acuvue |
| Harrow Eye, LLC | $210.93 | 2025 | Vevye |
| Dompe US, INC. | $195.31 | 2025 | Oxervate |
| Abbvie INC. | $139.67 | 2024 | |
| Coopervision INC. | $134.19 | 2023-2024 | Myday Contact Lens |
| Amgen INC. | $121.25 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $114.99 | 2025 | |
| New World Medical,INC. | $113.66 | 2023 | |
| Allergan, INC. | $97.31 | 2022 | |
| Astellas Pharma US INC | $24.36 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexia Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.